Towards volumetric thresholds in RECIST 1.1: Therapeutic response assessment in hepatic metastases

Eur Radiol. 2018 Nov;28(11):4839-4848. doi: 10.1007/s00330-018-5424-0. Epub 2018 May 7.

Abstract

Objectives: To empirically determine thresholds for volumetric assessment of response and progress of liver metastases in line with the unidimensional RECIST thresholds.

Methods: Patients with metastatic colorectal cancer initially enrolled in a multicentre clinical phase-III trial were included. In all CT scans, the longest axial diameters and volumes of hepatic lesions were determined semi-automatically. The sum of diameters and volumes of 1, ≤2 and ≤5 metastases were compared to all previous examinations. Volumetric thresholds corresponding to RECIST 1.1 thresholds were predicted with loess-regression. In sensitivity analysis, the concordances of proposed thresholds, weight-maximizing thresholds and thresholds from loess-regression were compared. Classification concordance for measurements of ≤2 metastases was further analyzed.

Results: For measurements of ≤2 metastases, 348 patients with 629 metastases were included, resulting in 4,773 value pairs. Regression analysis yielded volumetric thresholds of -65.3% for a diameter change of -30%, and +64.6% for a diameter change of +20%. When comparing measurements of unidimensional RECIST assessment with volumetric measurements, there was a concordance of significant progress (≥+20% and ≥+65%) in 88.3% and of significant response (≤-30% and ≤-65%) in 85.0%.

Conclusions: In patients with hepatic metastases, volumetric thresholds of +65% and -65% were yielded corresponding to RECIST thresholds of +20% and -30%.

Key points: • Volumes and diameters of liver metastases from colorectal cancer were determined. • Volumetric thresholds of +65%/-65% corresponding to RECIST 1.1 are proposed. • Comparing both measurements, concordance was 88.3% (significant progress) and 85.0% (significant response).

Keywords: Image interpretation, computer-assisted; Liver; Neoplasm metastasis; Response evaluation criteria in solid tumors; Tomography, X-Ray computed.

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Bevacizumab / therapeutic use
  • Cetuximab / therapeutic use
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Liver Neoplasms* / diagnostic imaging
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / secondary
  • Male
  • Middle Aged
  • Radiographic Image Enhancement
  • Reproducibility of Results
  • Response Evaluation Criteria in Solid Tumors*
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods*

Substances

  • Antineoplastic Agents
  • Bevacizumab
  • Cetuximab